Research article summary (published 30 Oct 2009):

IDO and outcomes in ovarian cancer.

Full Abstract

No abstract is available for this article. See 'Journal and Publication Information' further down the page for details that may assist you in locating this article in electronic or hard copy media. The 'Related articles' section also further down the page, where available, may show links to abstracts of articles covering similar topics.

Author information

Author/s: Nelson, Brad H (BH);

Journal and publication information

Publication Type: Comment; Editorial

Journal: Gynecologic oncology (Gynecol Oncol), published in United States. (Language: eng)

Reference: 2009-Nov; vol 115 (issue 2) : pp 179-80

Dates: Created 2009/10/13; Completed 2009/10/19;

PMID: 19822256, status: MEDLINE (last retrieval date: 10/19/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

Comments and Corrections

CommentOn: Gynecol Oncol. 2009 Nov;115(2):185-92. (PMID: 19665763)

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Antineoplastic Combined Chemotherapy Protocols - pharmacology CD8-Positive T-Lymphocytes - immunology Drug Synergism Female Humans Indoleamine-Pyrrole 2,3,-Dioxygenase - antagonists & inhibitors; biosynthesis; immunology

Indoleamine-Pyrrole 2,3,-Dioxygenase - antagonists & inhibitors; biosynthesis; immunology Lymphocytes, Tumor-Infiltrating - immunology Ovarian Neoplasms - drug therapy; enzymology; immunology Paclitaxel - administration & dosage; pharmacology Prognosis Tryptophan - administration & dosage; analogs & derivatives; pharmacology

Associated Chemicals: 1-methyltryptophan (0) ; Paclitaxel (33069-62-4) ; Tryptophan (73-22-3) ; Indoleamine-Pyrrole 2,3,-Dioxygenase (EC 1.13.11.42)

Related articles

These are the highest related articles currently in the database:

• Should we be using cimetidine to premedicate patients receiving docetaxel or paclitaxel? 29 Sep 2004
• Induction of thymidine phosphorylase expression and enhancement of Furtulon sensitivity by Taxol in a human ovarian carcinoma cell line. 29 Apr 2003
• Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. 13 Feb 2002
• Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status. 28 Feb 2004
• Involvement of aminopeptidase N in enhanced chemosensitivity to paclitaxel in ovarian carcinoma in vitro and in vivo. 13 May 2007
• Taxol-induced apoptosis in human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independent. 30 May 2002
• Interaction of cisplatin, paclitaxel and adriamycin with the tumor suppressor PTEN. 30 Oct 2001
• Effect of chemotherapy on the mutation frequency of ovarian cancer cells at the HPRT locus. 29 Apr 2005
• 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Aug 2007
• Potent inhibition of tumor survival in vivo by beta-lapachone plus taxol: combining drugs imposes different artificial checkpoints. 7 Nov 1999

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.